Skip to main content

Table 3 Pharmacokinetic parameters of Filgrastim and Pegfilgrastim

From: Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans

Parameter

Meaning

Filgrastim

Pegfilgrastim

k sc

subcutaneous absorption [h−1]

0.161

0.107

k m

Michaelis-Menten constant of

34.7

5.5

 

subcutaneous elimination [μg]

  

v max

Maximum of subcutaneous

67.3

16.5

 

elimination [h−1]

  

k u

unspecific elimination [h−1]

0.441

0.087

k m GRA

Michaelis-Menten constant of

22.4

30.8

 

specific elimination [μg]

  

v max GRA

Maximum of specific elimination [h−1]

4.77

5.16

k cp

transition central to peripheral [h−1]

0.000

0.075

k pc

transition peripheral to central [h−1]

-

0.548

V D

distribution volume [l]

1.156

4.091

C G − CSF cent _ ref

reference G-CSF serum concentration μ g l

0.02

  1. Compared to Pegfilgrastim, we estimated that Filgrastim is more easily absorbed from the subcutaneous compartment, has a lower bioavailability (see Figure3) and a higher specific and unspecific elimination. Reversible binding is neglectable for Filgrastim but not for Pegfilgrastim. The distribution volume is higher for Pegfilgrastim than for Filgrastim.